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“The most fruitful basis for the discovery of a new drug
is to start with an old one” is a citation from Sir James
Black’s Nobel laureate (1988).
The background of this statement lies in the fact that
most drugs are able to bind to multiple protein targets in
the human body, this is known as polypharmacology.
This behaviour can lead to unwanted side effects, and
innovative research to avoid such adverse properties is of
great importance. Paradoxically, polypharmacology can
also be used to create new therapeutic approaches, as the
protein to which a drug binds causing a side effect in one
case, can be the main target for another treatment. Many
cases report about the problems and opportunities of
polypharmacology.
Aims
In order for a drug to bind to multiple targets, the interac-
tion sites of these targets must be similar on a molecular
level. Using KRIPO (Key Representation of Interaction in
POckets) [1] with specially developed pharmacophore fin-
gerprints, we provide an objective method to accurately
describe protein interactions.
Results
KRIPO was used to explain the molecular mechanism of
adverse drug effects of HMG-CoA reductase inhibitors,
better known as statins. A previously unknown binding
site for statins in cytochrome b, the major subunit of
mitochondrial complex III of the oxidative phosphoryla-
tion system, was predicted by KRIPO.
Conclusion
Combining docking studies with KRIPO and experimen-
tal data on complex III inhibition enabled us to explain
the molecular details of statin binding to the predicted
binding site.
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